Management of Pigmented Villonodular Synovitis (PVNS): an Orthopedic Surgeon’s Perspective

[1]  G. Mödder.  Radiosynoviorthesis (Radiation Synovectomy) , 2020, Clinical Nuclear Medicine.

[2]  J. Desai,et al.  Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor , 2019, Scientific Reports.

[3]  David M. Thomas,et al.  Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial , 2019, The Lancet.

[4]  J. Wunder,et al.  Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints: A Study Based on a Multicenter-Pooled Database of 31 International Sarcoma Centers. , 2019, The Journal of bone and joint surgery. American volume.

[5]  J. Wunder,et al.  Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. , 2019, The Lancet. Oncology.

[6]  R. Tiling,et al.  The effects of radiosynoviorthesis in pigmented villonodular synovitis of the knee , 2018, Archives of Orthopaedic and Trauma Surgery.

[7]  A. Sternheim,et al.  Inconclusive benefit of adjuvant 90Yttrium hydroxyapatite to radiosynovectomy for diffuse‐type tenosynovial giant‐cell tumour of the knee , 2018, The bone & joint journal.

[8]  J. Blay,et al.  Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. , 2018, The Lancet. Oncology.

[9]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  H. Schreuder,et al.  Higher incidence rates than previously known in tenosynovial giant cell tumors , 2017, Acta orthopaedica.

[11]  S. Cannon,et al.  Pigmented villonodular synovitis of the knee: A retrospective analysis of 214 cases at a UK tertiary referral centre. , 2017, The Knee.

[12]  S. Papastergiou,et al.  Arthroscopically-assisted mini open partial synovectomy for the treatment of localized pigmented villonodular synovitis of the knee. A retrospective comparative study with long-term follow up , 2017, International Orthopaedics.

[13]  I. Judson,et al.  UK guidelines for the management of soft tissue sarcomas , 2016, Clinical Sarcoma Research.

[14]  S. Ferrari,et al.  Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives. , 2016, European journal of cancer.

[15]  J. Blay,et al.  CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. , 2015, The Lancet. Oncology.

[16]  M. van de Rijn,et al.  Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. , 2015, The New England journal of medicine.

[17]  J. Wunder,et al.  The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis. , 2015, The bone & joint journal.

[18]  C. Antonescu,et al.  Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. , 2015, European journal of cancer.

[19]  Q. Bi,et al.  A comparison of open and arthroscopic surgery for treatment of diffuse pigmented villonodular synovitis of the knee , 2014, Knee Surgery, Sports Traumatology, Arthroscopy.

[20]  J. Wunder,et al.  Combined arthroscopic and open synovectomy for diffuse pigmented villonodular synovitis of the knee , 2014, Knee Surgery, Sports Traumatology, Arthroscopy.

[21]  K. Weiss,et al.  Does Combined Open and Arthroscopic Synovectomy for Diffuse PVNS of the Knee Improve Recurrence Rates? , 2013, Clinical orthopaedics and related research.

[22]  P. Hogendoorn,et al.  The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). , 2012, The Journal of bone and joint surgery. British volume.

[23]  R. West,et al.  Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive Synovitides , 2007, The American journal of surgical pathology.

[24]  Robert J. Marinelli,et al.  A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Houman,et al.  Tissue crosslinks concentrations in normal joints and chronic articular diseases , 1997, Annals of the rheumatic diseases.